Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Praluent neurocognitive function study in high-risk hypercholesterolemia
NL-OMON45390Phase 4Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypercholesterolemia and familial hypercholesterolemia (FH) comparing Praluent with Placebo (2 arms). Primary endpoint: Change in CANTAB Spatial Working Memory strategy score. Planned start Nov 2016; status: withdrawn.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON45390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45390.